About Mateon Therapeutics (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:MATN
- Previous Symbol: NASDAQ:MATN
- CUSIP: N/A
- Web: www.mateon.com
- Current Ratio: 4.57%
- Quick Ratio: 4.57%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $0.47 per share
- Price / Book: 0.50
- Trailing EPS: ($0.55)
- Net Income: ($13,650,000.00)
- Return on Equity: -168.66%
- Return on Assets: -144.46%
- Employees: 16
- Outstanding Shares: 26,550,000
Frequently Asked Questions for Mateon Therapeutics (OTCMKTS:MATN)
What is Mateon Therapeutics' stock symbol?
Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."
How were Mateon Therapeutics' earnings last quarter?
Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter. View Mateon Therapeutics' Earnings History.
Where is Mateon Therapeutics' stock going? Where will Mateon Therapeutics' stock price be in 2017?
4 brokers have issued 12 month price objectives for Mateon Therapeutics' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Mateon Therapeutics' share price to reach $2.00 in the next year. View Analyst Ratings for Mateon Therapeutics.
Who are some of Mateon Therapeutics' key competitors?
Some companies that are related to Mateon Therapeutics include Critical Outcome Technologies (COTQF), Acura Pharmaceuticals (ACUR), M Pharmaceutical (MPHMF), ESSA Pharma (EPIX), Strata Skin Sciences (SSKN), Secure Point Technologies (IMSC), Lombard Medical (EVARF), Windtree Therapeutics (WINT), TearLab Corporation (TEAR), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), BG Medicine (BGMD), Echo Therapeutics (ECTE), Imris (IMRSQ) and Sino Pharmaceut (SBMFF).
Who are Mateon Therapeutics' key executives?
Mateon Therapeutics' management team includes the folowing people:
- William D. Schwieterman M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
- Matthew M. Loar CPA, Chief Financial Officer, Principal Accounting Officer (Age 51)
- David Chaplin Ph.D., Chief Scientific Officer, Director (Age 59)
- Simon C Pedder Ph.D., Director (Age 56)
- Donald R. Reynolds, Independent Director (Age 54)
- Bobby W. Sandage Jr., Ph.D., Independent Director (Age 63)
How do I buy Mateon Therapeutics stock?
Shares of Mateon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mateon Therapeutics' stock price today?
One share of Mateon Therapeutics stock can currently be purchased for approximately $0.24.
How big of a company is Mateon Therapeutics?
Mateon Therapeutics has a market capitalization of $6.23 million. The biopharmaceutical company earns ($13,650,000.00) in net income (profit) each year or ($0.55) on an earnings per share basis. Mateon Therapeutics employs 16 workers across the globe.
How can I contact Mateon Therapeutics?
Mateon Therapeutics' mailing address is 701 Gateway Blvd Ste 210, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-6357000 or via email at [email protected]
MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Mateon Therapeutics (OTCMKTS:MATN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$2.00|
Consensus Price Target History for Mateon Therapeutics (OTCMKTS:MATN)
Analysts' Ratings History for Mateon Therapeutics (OTCMKTS:MATN)
(Data available from 11/18/2015 forward)
|8/1/2017||Maxim Group||Reiterated Rating||Hold|
|4/20/2017||Roth Capital||Initiated Coverage||Buy -> Buy||$2.00|
|3/13/2017||HC Wainwright||Initiated Coverage||Buy||$2.00|
|3/13/2017||Rodman & Renshaw||Reiterated Rating||Buy -> Buy||$2.00|
|1/29/2016||S&P Equity Research||Lower Price Target||$0.64 -> $0.58|
Earnings History and Estimates Chart for Mateon Therapeutics (OTCMKTS:MATN)
Earnings History by Quarter for Mateon Therapeutics (OTCMKTS MATN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Mateon Therapeutics (OTCMKTS:MATN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Mateon Therapeutics (OTCMKTS:MATN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mateon Therapeutics (OTCMKTS MATN)
Insider Ownership Percentage: 4.50%
Insider Trades by Quarter for Mateon Therapeutics (OTCMKTS MATN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/16/2016||Donald Rogers Reynolds||Director||Buy||30,000||$0.35||$10,500.00|| |
|6/28/2013||Peter Langecker||CEO||Buy||3,000||$2.75||$8,250.00|| |
|6/25/2013||Peter Langecker||CEO||Buy||2,000||$2.79||$5,580.00|| |
Headline Trends for Mateon Therapeutics (OTCMKTS:MATN)
Latest Headlines for Mateon Therapeutics (OTCMKTS MATN)
Mateon Therapeutics (OTCMKTS MATN) Chart for Saturday, November, 18, 2017